Dr. Luo founded HM Venture Partners in 2018. He has over 25 years of professional experience in investment, entrepreneurship, operations and management, life sciences research, and clinical practice.
Dr. Luo co-founded HM Healthcare Management Services (HMHMS) with Hillhouse Investment Group and Mayo Clinic in 2014 and has been serving as the CEO. He subsequently started several influential healthcare platform companies in China, such as HM Technology and HM Digital Technology. Under his guidance, HMHMS also practiced diversified healthcare investments globally.
Prior to founding HMHMS, Dr. Luo was a senior investment officer at Mayo Clinic and led multi-billion dollar investments globally. Earlier, Dr. Luo worked on neural stem cell research for 5 years at the Neurobiotechnology Center at the Ohio State University and completed his ophthalmology residency training at Peking Union Hospital in Beijing.
Dr. Luo received his MBA from the Ohio State University and MD from Peking University Health Science Center.
Jane is a serial entrepreneur and operating executive who has launched 7 technology startups as well as advised numerous clients, from multinationals to early commercialization stage companies whose missions are to make significant healthcare and/or environmental impacts.
Prior to joining HM Venture Partners, Jane served as VP Strategy and Business Development of Senseer Health, a developer of smart medical device therapies for chronic conditions. Jane joined Senseer from UrLoop, a software engagement platform for senior living, where she served as CEO and orchestrated its sale to Senseer.
Jane co-founded merchant bank, Jane Capital Partners in 2001. Startups launched by Jane Capital where Jane served on the boards include Smart Wires Inc. (private) and Zenergy Power plc (IPO). Investee companies raised over $300M. Earlier in her career, Jane served as Executive Director of venture fund, WI Harper Group.
Jane holds a BS from Syracuse University and an MS from the University of Connecticut.
Dr. Lu has more than three decades of hands-on experience in cross border investments in biotech, medtech, and healthcare services. Dr. Lu joined HM Venture Partners as a venture partner in 2022.
Dr. Lu was the Founding and Managing Partner of New Vision Ventures (NVV). Prior to that, Dr. Lu served as a Partner for Israel Infinity Group and an Executive Director for Toucan Capital (USA). He has previously invested in over 30 companies.
Formerly Dr. Lu was a senior research scientist at Yale School of Medicine and participated in translational research on therapeutic antibody drugs and anti-virus vaccines. In addition, Dr. Lu practiced cardiology in China for years.
Dr. Lu received his MBA from Yale School of Management (SOM) and Ph.D. of Medical Science Peking University Health Science Center.
Dr. Guo has more than 20 years of biological research experience. She joined HM Venture Partners in 2022, mainly responsible for conducting scientific research review of the potential investment companies and deal sourcing.
Prior to joining HM Venture Partners, Dr. Guo served as an assistant professor at Mayo Clinic for ten years, guiding independent laboratories to engage in scientific research on fat metabolism, fatty acid lipotoxicity and liver cancer.
Previously, Dr. Guo worked as a postdoctoral researcher at University of California, San Francisco. Her representative works were published in Nature, Cell Metabolism and other peer reviewed top scientific research journals.
Dr. Guo received her Ph.D. in Biochemistry from Brandeis University and B.S. in Biochemistry and Molecular Biology from Peking University.
Founded in 2019, HM Venture Partners is a healthcare venture capital firm that works with high growth biotech and medtech companies globally and in all stages. Currently HM has 3 funds under management with AUM in excess of $600M. The third fund, HM Healthcare Fund I, was recently launched to primarily invest in healthcare breakthroughs in the US. HM’s funds consistently demonstrate robust results. The team of HM Venture Partners successfully started and managed HM Healthcare Management Services, a joint venture between Hillhouse Investment Group and Mayo Clinic.
In-depth domain knowledge and a global perspective: Our seasoned team is dedicated to identifying the most innovative opportunities to address significant unmet needs globally and to working with extraordinary entrepreneurs to harness the power of breakthroughs.
An unparalleled ecosystem: Our network of academic institutions, physician networks, and renown industry experts and related operating entities enable unique access to proprietary deal flow, industry insights, prime clinical trial sites, cross-border business development, collaborations and partnerships.
Cycle-tested financing strategies: We leverage previous successes in structuring flexible transactions across capital cycles to create significant post-value increases.
Robert Luo
Founding and Managing Partner
Harry Hoffman
Venture Partner
David Herbert
Venture Partner
Peter Lu
Venture Partner
Yi Guo
Chief Scientist Officer
Jane Lindner
Vice President
HM Venture Partners is a healthcare venture capital firm, committed to helping early and growth-stage healthcare companies achieve accelerated development by leveraging HM team’s expertise and extensive global ecosystem.
We invest around the world from our offices in San Francisco (CA), Rochester (MN), and Beijing.
Here’s what a few of our successful entrepreneurs have to say:
“HM was invaluable in helping secure FDA approval for our urologic device products. Their support included helping strategize negotiations with a strategic investor, advising on operational efficiencies and team communication, and leveraging their clinical network and distribution channels to access the massive Chinese market. HM’s contributions have made a huge difference for us.”
David Perry, CEO
“HM has played a crucial role in providing financial and operational support at the most opportune times for OncoImmune and OncoC4. We greatly value HM as an investor and trusted partner in both OncoImmune and OncoC4."
Dr. Yang Liu, Founder and CEO
“HM Venture Partners has been an outstanding partner for Osteal. Their support both financial and operational has been critical to successfully achieving our goals over the last 18 months. We look forward to a highly productive ongoing partnership as we enter our next phase of growth.”
David Thompson, CEO
“We rate HM as an extraordinary investor. They guided Coherent through a tough bear market in securing enough funding to continue our global clinical trials, providing access to highly relevant industry experts, and making introductions to valuable clinical trial sites and potential collaborations with global business partners. We look forward to their ongoing leadership and guidance for Coherent’s success.”.
Dr. Robert Huang, Founder and CEO
OncoImmune Inc. is an innovative biopharmaceutical company focused on oncology and immune diseases. The pipeline covers viral pneumonia, graft-versus-host disease (GVHD), autoimmune diseases, tumor immunotherapy, etc., all of which are the world's First-in-Class or First-in-Mechanisms of Action drug candidates. HM identified the company through its global ecosystem and led the investment in the company 2 months prior to the acquisition by Merck & Co., with an upfront payment of $425M, milestone payments, sales-based payments, plus shares of spin-off companies. In addition, HM supported the management team identify clinical trial sites for fast patient enrollment in the pandemic and convinced shareholders of an acquisition due to prime market timing.
Founded in Dec 2020 in Maryland, US, OncoC4 is a spin-off company from OncoImmune, which was acquired by Merck & Co. in 2020. All pipelines are First-in-Class or First-in-Mechanisms of Action candidates. The co-founders are serial entrepreneurs and reputable scientists in the field of immunotherapy. HM has built trusted relationship with the management team through the previous investment in OncoImmune and HM was the only institutional investor invited by the management team for additional investment in OncoC4. HM analyzed the preclinical and clinical data of all CTLA4 drugs thoroughly and believed that ONC-392 has the potential to become Best-in-Class with high expected peak sales. In addition, the other products in the pipeline have potential to become blockbuster drugs. Taking advantage of the bear market, HM also obtained favorable deal terms.
Within 9 months of HM’s investment, BioNTech and OncoC4 announced a strategic collaboration to co-develop and commercialize novel checkpoint antibody in multiple solid tumor indications. OncoC4 will receive $200 million upfront and is eligible to receive development, regulatory and commercial milestone payments and double-digit tiered royalties.
Founded in 2022, Airiver Medical Inc. develops Drug Coated Balloons (DCB) for recurring airway stenosis and asthma. The product solves unmet medical needs with a large potential market size and is expected to become the first-line therapy. Previously HM had successfully invested in 2 DCB technology companies started by the same entrepreneur, Urotronic for urology stenosis and GIE for gastrointestinal stenosis.
As a result, HM actively explored the application of DCB technology in the respiratory tract with systematic and in-depth internal research. With encouraging research outcomes, HM convinced the entrepreneur to incubate a new company, Airiver, which is the first company applying the DCB-based product to respiratory tract related diseases in the world. HM assisted the entrepreneur in the spin-off of Airiver and helped the entrepreneur structure the deal with a reasonable valuation.
Robert Luo
Founding and Managing Partner
Dr. Luo founded HM Venture Partners in 2018. He has over 25 years of professional experience in investment, entrepreneurship, operations and management, life sciences research, and clinical practice.
Dr. Luo co-founded HM Healthcare Management Services (HMHMS) with Hillhouse Investment Group and Mayo Clinic in 2014 and has been serving as the CEO. He subsequently started several influential healthcare platform companies in China, such as HM Technology and HM Digital Technology. Under his guidance, HMHMS also practiced diversified healthcare investments globally.
Prior to founding HMHMS, Dr. Luo was a senior investment officer at Mayo Clinic and led multi-billion dollar investments globally. Earlier, Dr. Luo worked on neural stem cell research for 5 years at the Neurobiotechnology Center at the Ohio State University and completed his ophthalmology residency training at Peking Union Hospital in Beijing.
Dr. Luo received his MBA from the Ohio State University and MD from Peking University Health Science Center.
Jane Lindner
Vice President
Jane is a serial entrepreneur and operating executive who has launched 7 technology startups as well as advised numerous clients, from multinationals to early commercialization stage companies whose missions are to make significant healthcare and/or environmental impacts.
Prior to joining HM Venture Partners, Jane served as VP Strategy and Business Development of Senseer Health, a developer of smart medical device therapies for chronic conditions. Jane joined Senseer from UrLoop, a software engagement platform for senior living, where she served as CEO and orchestrated its sale to Senseer.
Jane co-founded merchant bank, Jane Capital Partners in 2001. Startups launched by Jane Capital where Jane served on the boards include Smart Wires Inc. (private) and Zenergy Power plc (IPO). Investee companies raised over $300M. Earlier in her career, Jane served as Executive Director of venture fund, WI Harper Group.
Jane holds a BS from Syracuse University and an MS from the University of Connecticut.
Peter Lu
Venture Partner
Dr. Lu has more than three decades of hands-on experience in cross border investments in biotech, medtech, and healthcare services. Dr. Lu joined HM Venture Partners as a venture partner in 2022.
Dr. Lu was the Founding and Managing Partner of New Vision Ventures (NVV). Prior to that, Dr. Lu served as a Partner for Israel Infinity Group and an Executive Director for Toucan Capital (USA). He has previously invested in over 30 companies.
Formerly Dr. Lu was a senior research scientist at Yale School of Medicine and participated in translational research on therapeutic antibody drugs and anti-virus vaccines. In addition, Dr. Lu practiced cardiology in China for years.
Dr. Lu received his MBA from Yale School of Management (SOM) and Ph.D. of Medical Science Peking University Health Science Center.
Yi Guo
Chief Scientist Officer
Dr. Guo has more than 20 years of biological research experience. She joined HM Venture Partners in 2022, mainly responsible for conducting scientific research review of the potential investment companies and deal sourcing.
Prior to joining HM Venture Partners, Dr. Guo served as an assistant professor at Mayo Clinic for ten years, guiding independent laboratories to engage in scientific research on fat metabolism, fatty acid lipotoxicity and liver cancer.
Previously, Dr. Guo worked as a postdoctoral researcher at University of California, San Francisco. Her representative works were published in Nature, Cell Metabolism and other peer reviewed top scientific research journals.
Dr. Guo received her Ph.D. in Biochemistry from Brandeis University and B.S. in Biochemistry and Molecular Biology from Peking University.
Harry Hoffman
Venture Partner
David Herbert
Venture Partner
Founded in 2019, HM Venture Partners is a healthcare venture capital firm that works with high growth biotech and medtech companies globally and in all stages. Currently HM has 3 funds under management with AUM in excess of $600M. The third fund, HM Healthcare Fund I, was recently launched to primarily invest in healthcare breakthroughs in the US. HM’s funds consistently demonstrate robust results. The team of HM Venture Partners successfully started and managed HM Healthcare Management Services, a joint venture between Hillhouse Investment Group and Mayo Clinic.
In-depth domain knowledge and a global perspective: Our seasoned team is dedicated to identifying the most innovative opportunities to address significant unmet needs globally and to working with extraordinary entrepreneurs to harness the power of breakthroughs.
An unparalleled ecosystem: Our network of academic institutions, physician networks, and renown industry experts and related operating entities enable unique access to proprietary deal flow, industry insights, prime clinical trial sites, cross-border business development, collaborations and partnerships.
Cycle-tested financing strategies: We leverage previous successes in structuring flexible transactions across capital cycles to create significant post-value increases.
HM Venture Partners is a healthcare venture capital firm, committed to helping early and growth-stage healthcare companies achieve accelerated development by leveraging HM team’s expertise and extensive global ecosystem.
We invest around the world from our offices in San Francisco (CA), Rochester (MN), and Beijing.
Here’s what a few of our successful entrepreneurs have to say:
“HM was invaluable in helping secure FDA approval for our urologic device products. Their support included helping strategize negotiations with a strategic investor, advising on operational efficiencies and team communication, and leveraging their clinical network and distribution channels to access the massive Chinese market. HM’s contributions have made a huge difference for us.”
David Perry, CEO
“HM has played a crucial role in providing financial and operational support at the most opportune times for OncoImmune and OncoC4. We greatly value HM as an investor and trusted partner in both OncoImmune and OncoC4."
Dr. Yang Liu, Founder and CEO
“HM Venture Partners has been an outstanding partner for Osteal. Their support both financial and operational has been critical to successfully achieving our goals over the last 18 months. We look forward to a highly productive ongoing partnership as we enter our next phase of growth.”
David Thompson, CEO
“We rate HM as an extraordinary investor. They guided Coherent through a tough bear market in securing enough funding to continue our global clinical trials, providing access to highly relevant industry experts, and making introductions to valuable clinical trial sites and potential collaborations with global business partners. We look forward to their ongoing leadership and guidance for Coherent’s success.”.
Dr. Robert Huang, Founder and CEO
OncoImmune Inc. is an innovative biopharmaceutical company focused on oncology and immune diseases. The pipeline covers viral pneumonia, graft-versus-host disease (GVHD), autoimmune diseases, tumor immunotherapy, etc., all of which are the world's First-in-Class or First-in-Mechanisms of Action drug candidates. HM identified the company through its global ecosystem and led the investment in the company 2 months prior to the acquisition by Merck & Co., with an upfront payment of $425M, milestone payments, sales-based payments, plus shares of spin-off companies. In addition, HM supported the management team identify clinical trial sites for fast patient enrollment in the pandemic and convinced shareholders of an acquisition due to prime market timing.
Founded in Dec 2020 in Maryland, US, OncoC4 is a spin-off company from OncoImmune, which was acquired by Merck & Co. in 2020. All pipelines are First-in-Class or First-in-Mechanisms of Action candidates. The co-founders are serial entrepreneurs and reputable scientists in the field of immunotherapy. HM has built trusted relationship with the management team through the previous investment in OncoImmune and HM was the only institutional investor invited by the management team for additional investment in OncoC4. HM analyzed the preclinical and clinical data of all CTLA4 drugs thoroughly and believed that ONC-392 has the potential to become Best-in-Class with high expected peak sales. In addition, the other products in the pipeline have potential to become blockbuster drugs. Taking advantage of the bear market, HM also obtained favorable deal terms.
Within 9 months of HM’s investment, BioNTech and OncoC4 announced a strategic collaboration to co-develop and commercialize novel checkpoint antibody in multiple solid tumor indications. OncoC4 will receive $200 million upfront and is eligible to receive development, regulatory and commercial milestone payments and double-digit tiered royalties.
Founded in 2022, Airiver Medical Inc. develops Drug Coated Balloons (DCB) for recurring airway stenosis and asthma. The product solves unmet medical needs with a large potential market size and is expected to become the first-line therapy. Previously HM had successfully invested in 2 DCB technology companies started by the same entrepreneur, Urotronic for urology stenosis and GIE for gastrointestinal stenosis.
As a result, HM actively explored the application of DCB technology in the respiratory tract with systematic and in-depth internal research. With encouraging research outcomes, HM convinced the entrepreneur to incubate a new company, Airiver, which is the first company applying the DCB-based product to respiratory tract related diseases in the world. HM assisted the entrepreneur in the spin-off of Airiver and helped the entrepreneur structure the deal with a reasonable valuation.